GPR18, still considered an orphan receptor, may respond to endocannabinoids, whose canonical receptors are CB 1 and CB 2 . GPR18 and CB 2 receptors share a role in peripheral immune response regulation and are coexpressed in microglia, which are immunocompetent cells in the central nervous system (CNS). We aimed at identifying heteroreceptor complexes formed by GPR18 and CB 1 R or CB 2 R in resting and activated microglia. Receptor-receptor interaction was assessed using energy-transfer approaches, and receptor function by determining cAMP levels and ERK1/2 phosphorylation in heterologous cells and primary cultures of microglia. Heteroreceptor identification in primary cultures of microglia was achieved by in situ proximity ligation assays. Energy transfer results showed interaction of GPR18 with CB 2 R but not with CB 1 R. CB 2 -GPR18 heteroreceptor complexes displayed particular functional properties (heteromer prints) often consisting of negative cross-talk (activation of one receptor reduces signaling arising from the partner receptor) and cross-antagonism (the response of one of the receptors is blocked by a selective antagonist of the partner receptor). Activated microglia showed the heteromer print (negative cross-talk and bidirectional cross-antagonism) and increased expression of CB 2 R and GPR18. Due to the important role of CB 2 R in neuroprotection, we further investigated heteroreceptor occurrence in primary cultures of microglia from transgenic mice overexpressing human APP Sw,Ind , an Alzheimer's disease model. Microglial cells from transgenic mice showed the heteromer print and functional interactions that were similar to those found in cells from wild-type animals that were activated by treatment with lipopolysaccharide and interferon-γ. Our results suggest that GPR18 and its heteromers may play important roles in neurodegenerative processes.
Introduction
GPR18, a G-protein-coupled receptor (GPCR) discovered in 1997 [20] , is still an orphan receptor although some agonists have been reported. Abnormal cannabidiol (Abn-CBD) is a nonselective GPR18 agonist [19] ; for this reason GPR18 is also known as Abn-CBD receptor. N-arachidonoylglycine (NAGly), which arises from anandamide (AEA; N-arachidonoylethanolamine) metabolism [6] , was suggested by Kohno et al. [24] and later by McHugh et al. [33] , Takenouchi et al. [52] and Console-Bram et al. [13] as the endogenous ligand. In contrast, some authors describe GPR18 as unresponsive to NAGly [28, 47, 17] . The receptor became of interest in the cannabinoid research field because cannabinoids may activate it [22] . In summary, despite potential activation by endocannabinoids and NAGly, GPCR18 still remains as an orphan receptor (IUPHAR/BPS: www.guidetopharmacology.org).
GPR18 is widely expressed in different tissues and cell types. GPR18 expression was first described in spleen, thymus, bone marrow, leucocytes and macrophages [20, 53, 24, 46, 52, 3] . However, receptor is also expressed in the central nervous system (CNS) [53, 46, 44] , in particular in microglia [54] , in testis, ovary, lungs, intestine [20, 53] , eye [10] and cancerous cells [33] [34] 45] .
In the periphery, regulating the immune system, GPR18 is involved in resolving inflammation [8] , regulating macrophage apoptosis [52] and controlling the fate of intestine intraepithelial lymphocytes following bone marrow transplantation [3] . It is also involved in regulating hemodynamic responses [43, 44, 1, 31] , cell migration [54, 33] and intraocular pressure [35] . Furthermore, its activation produce analgesia [23] .
GPR18 is a G i/o coupled receptor, as pertussis toxin (PTX) is able to block the decrease of intracellular cAMP levels elicited by one of the reported agonists, NAGly [24] . Intriguingly, it has been described that NAGly, Δ 9 -THC and Abn-CBD may increase intracellular Ca 2+ levels via GPR18, thus suggesting that the receptor is also able to couple to G q [24, 6] . In addition, activation of GPR18 by NAGly, Δ
9
-THC or Abn-CBD may lead to engagement of the MAP kinase pathway in a PTX-dependent fashion [33, 52] . Only Δ
-THC has been found to recruit ß-arrestins [55, 47] , thus suggesting that the receptor is prone to a markedly biased agonism depending on the structure of the ligand used in the assays.
Endocannabinoids, and natural and synthetic cannabinoids act via specific CB 1 and CB 2 cannabinoid receptors [26, 27, 30] . Activation of cannabinoid receptors (CB 1 R and CB 2 R), which are coupled to G i proteins, leads to an inhibition of adenylate cyclase and a decrease in the intracellular levels of a second messenger, cAMP. The CB 1 R is considered as the most abundant GPCR in the CNS, being present in neurons and in glia [4] ; in the CNS the CB 2 R is expressed in neurons in some restricted brain areas (see Ref. [25] and references therein) and in glia, mainly in activated microglia [9, 16] . Cannabinoid receptors may establish direct interactions and this may occur in some neurons of the globus pallidus where the two receptors are co-expressed [11, 51] , and in glial cells [38] .
Some authors have described that CB 2 R and GPR18 may work in cooperation to regulate microglial cell migration [19, 54] . As demonstrated for an increasing number of GPCRs, CB 1 R and CB 2 R may establish receptor-receptor interactions leading to CB 1 R-CB 2 R heteromers, which display particular characteristics with impact on neural regulation of neurotransmission and neuroinflammation [11, 38] . The two aims of this investigation were to look for potential interactions of GPR18 with cannabinoid CB 1 and/or CB 2 receptors, with a special focus on the CNS, where all three GPCRs are expressed, and to look for the physiological significance of CB 1 R/CB 2 R-GPR18 heteromer expression and signaling in activated microglial cells, as microglia are the immune competent cells in the CNS [18] . We identified the occurrence of CB 2 R-GPR18 heteroreceptor complexes in a heterologous expression system and in primary cultures of microglia in resting conditions and upon activation with LPS and IFN-γ. Functional assays were performed to detect the heteromer print, which was also identified in primary cultures of microglia from a transgenic mouse model of Alzheimer's disease. Microglial cells from the brain of transgenic mice expressed CB 2 R-GPR18 receptor complexes that behaved like those in cells from wildtype animals treated with LPS and IFN-γ. These results highlight the potential of GPR18 and CB 2 receptors in microglia for modulating or regulating neurodegeneration and neuroprotection.
Materials and methods

Expression vectors
cDNAs for the human version of CB 1 , CB 2 , GPR18 and GABA B receptors with sequences lacking the stop codon were obtained by PCR and subcloned to Rluc-containing vector (pRluc-N1; PerkinElmer, Wellesley, MA) using sense and antisense primers harboring unique restriction sites for HindIII and BamHI, to generate CB 1 R-Rluc, GPR18-Rluc and GABA B -Rluc fusion proteins, or subcloned to enhanced yellow fluorescent protein-containing vector (pEYFP-N1; Clontech, Heidelberg, Germany) using sense and antisense primers harboring unique restriction sites for BamHI and KpnI, to generate CB 1 R-YFP and CB 2 R-YFP fusion proteins, or using sense and antisense primers harboring unique restriction sites for BamHI and HindIII, to generate GPR18-YFP fusion protein.
Transgenic mouse model of Alzheimer's disease (AD)
APP Sw,Ind transgenic mice (line J9; C57BL/6 background) expressing human APP695 harboring the familial Alzheimeŕs disease-linked Swedish (K670N/M671L) and Indiana (V717F) mutations under the PDGFβ promoter were obtained by crossing heterozygous APP Sw,Ind with wild-type (WT) mice [37] . Mice at 2 days of age were genotyped individually by conventional PCR [15, 38] . Experimental procedures were conducted according to the Animal and Human Ethical Committee of the Universitat Autònoma de Barcelona (protocol CEEAH 2896, Generalitat Catalunya 8787) following the European Union guidelines. Experiments with primary cultures (see below) were performed blindly, without knowing the genotype, which was disclosed for data analysis.
Microglia isolation, cell culture and transient transfection
HEK-293T cells at passage 8-12 were grown in Dulbecco's modified Eagle's medium (DMEM) (Gibco, Paisley, Scotland, UK) supplemented with 2 mM L-glutamine, 100 U/ml penicillin/streptomycin, MEM NonEssential Amino Acids Solution (1/100) and 50% (v/v) heat inactivated Fetal Bovine Serum (FBS) (Invitrogen, Paisley, Scotland, UK). Cells were maintained in a humid atmosphere of 5% CO 2 at 37°C. Cells were transiently transfected with the PEI (PolyEthylenImine, SigmaAldrich) method as previously described [41] . To prepare primary microglial cultures, brain was removed from C57BL/6 or APP Sw,Ind mice of 2 days of age. Microglial cells, with a > 95% purity (according to Iba-1 immunoreactivity and Hoechst nuclei staining) were isolated as described elsewhere [38] and grown in DMEM medium supplemented with 2 mM L-glutamine, 100 U/ml penicillin/streptomycin, MEM Non-Essential Amino Acids Solution (1/100) and 5% (v/v) heat inactivated Fetal Bovine Serum (FBS) (Invitrogen, Paisley, Scotland, UK). In brief, samples were dissected, carefully stripped off the meninges and digested with 0.25% trypsin for 30 min at 37°C. Trypsinization was stopped by adding an equal volume of culture medium (Dulbecco's modified Eagle medium-F-12 nutrient mixture, fetal bovine serum 10%, penicillin 100 U/mL, streptomycin 100 µg/mL and amphotericin B 0.5 µg/ml) containing 160 mg/mL deoxyribonuclease I (all those reagents from Invitrogen). Cells were brought to a homogeneous suspension by repeated pipetting followed by passage through a 100 µm-pore mesh and pelleted (7 min, 200×g) . Glial cells were resuspended in medium and seeded at a density of 3.5 × 10 5 cell/ml in 6-well plates. Cultures were maintained at 37°C in humid 5% CO 2 atmosphere and medium was replaced at DIV 2 and once every week. For other assays cells were grown either in 6-well plates at a density of 500,000/well in 2 mL or directly in 96-well plates at a density of 50,000/well; each well having a volume of 0.2 mL. For cAMP assays, cells grown on 6-well plates were scrapped and placed in 384-well plates at a density of 2500 cells/well. Cell counting was assessed using trypan blue and a Countless II FL automated cell counter (Thermo Fisher Scientific-Life Technologies).
Bioluminescence resonance energy transfer (BRET) assays
HEK-293T cells growing in 6-well plates were transiently cotransfected with a constant amount of cDNA encoding for CB 1 
Immunostaining procedures
Cells were fixed in 4% paraformaldehyde for 15 min and washed twice with PBS containing 20 mM glycine before permeabilization with PBS-glycine containing 0.2% Triton X-100 (5 min incubation). HEK-293T cells were treated for 1 h with PBS containing 1% bovine serum albumin and labelled with a mouse anti-Rluc (1/100; MAB4400, Millipore) antibody, and subsequently treated with Cy3-conjugated anti-mouse (1/200; 715-166-150; Jackson ImmunoResearch (red)) IgG secondary antibody (1 h each). Specificity of antibodies was tested in untransfected HEK-293T cells (data not shown). Samples were washed several times and mounted with 30% Mowiol (Calbiochem). Samples were observed in a Leica SP2 confocal microscope (Leica Microsystems).
cAMP determination
Two hours before adding reagents, HEK-293T cells or microglial primary cultures were placed in serum-free medium. Then, cells were detached and suspended in medium containing 50 µM zardaverine. Cells were placed in 384-well plates (2500 cells/well), pretreated (15 min) with the corresponding antagonists -or vehicle -and stimulated with agonists (15 min) before adding 0.5 µM forskolin or vehicle (15 min). Readings were performed after 1 h of incubation at 25°C. Homogeneous time-resolved fluorescence energy transfer (HTRF) measures were performed using the Lance Ultra cAMP kit (PerkinElmer, Waltham, MA, USA). Fluorescence at 665 nm was analyzed on a PHERAstar Flagship plate reader equipped with an HTRF optical module (BMG Lab technologies, Offenburg, Germany). The value of reference (100%) was that achieved by 0.5 µM forskolin treatment. The effect of ligands was given in percentage respect to the reference value.
ERK phosphorylation assays
To determine ERK1/2 phosphorylation, 40,000 cells/well were plated in transparent Deltalab 96-well plates and kept at the incubator for 48 h. 2 to 4 h before the experiment, the medium was replaced by serum-free medium. Then, cells were pre-treated at 25°C for 10 min with vehicle or antagonists in serum-free DMEM medium and stimulated for an additional 7 min with agonists. Cells were then washed twice with cold PBS before addition of lysis buffer (20 min treatment). 10 µL of each supernatant were placed in white ProxiPlate 384-well plates and ERK 1/2 phosphorylation was determined using AlphaScreen®SureFire® kit (Perkin Elmer) following the instructions of the supplier and using an EnSpire® Multimode Plate Reader (PerkinElmer, Waltham, MA, USA). The value of reference (100%) was that achieved in the absence of any treatment (basal). The effect of ligands was given in percentage respect to the basal value.
Dynamic mass redistribution (DMR) assays
Cell mass redistribution induced upon receptor activation was detected by illuminating with polychromatic light the underside of a biosensor and measuring the changes in the wavelength of the reflected monochromatic light that is a sensitive function of the index of refraction. The magnitude of the wavelength shift (in picometers) is directly proportional to the amount of mass redistribution. HEK-293T cells were seeded in 384-well sensor microplates to obtain 70-80% confluent monolayers constituted by approximately 10,000 cells per well. Previous to the assay, cells were washed twice with assay buffer (HBSS with 20 mM HEPES, pH 7.15) and incubated 2 h with assaybuffer containing 0.1% DMSO (24°C, 30 µL/well). Hereafter, the sensor plate was scanned and a baseline optical signature was recorded for 10 min before adding 10 µL of the selective antagonists for 30 min followed by the addition of 10 µL of the selective agonists; all test compounds were dissolved in assay buffer. Then, DMR responses were monitored for at least 5000 s in an EnSpire® Multimode Plate Reader (PerkinElmer, Waltham, MA, USA). Results were analyzed using EnSpire Workstation Software v 4.10.
In situ proximity ligation assays (PLA)
Microglial primary cultures grown on glass coverslips were fixed in 4% paraformaldehyde for 15 min, washed with PBS containing 20 mM glycine to quench the aldehyde groups and permeabilized with the same buffer containing 0.05% Triton X-100 (5 min treatment). Fixed cells were incubated for 1 h at 37°with blocking solution (from PLA kit, see below) and subsequently treated with specific antibodies against CB 2 (SC-25494 raised in rabbit; 1/100) and GPR18 (SC-79501, raised in goat; 1/100) receptors and processed using the PLA probes detecting rabbit and goat antibodies (Duolink II PLA probe anti-Rabbit plus and Duolink II PLA probe anti-Goat minus). Specificity of antibodies was tested in untransfected HEK-293T cells (data not shown). Duolink II in situ PLA detection kit (Duolink® In Situ Detection Reagents Red, DUO92008, developed by Olink Bioscience, Uppsala, Sweden; and now distributed by SigmaAldrich as Duolink® using PLA® Technology) was used to detect the presence/absence of receptor clusters in the samples, which were incubated with the ligation solution for 1 h, washed and subsequently incubated with the amplification solution for 100 min (both steps at 37°C in a humid chamber). Nuclei were stained with Hoechst (1/100; SigmaAldrich). Mounting was performed using 30% Mowiol (Calbiochem). Negative controls were performed by omitting the primary anti-GPR18 antibody. Samples were observed in a Leica SP2 confocal microscope (Leica Microsystems, Mannheim, Germany) equipped with an apochromatic 63X oil-immersion objective (N.A. 1.4), and 405 nm and 561 nm laser lines. For each field of view a stack of two channels (one per staining) and 5 Z stacks with a step size of 1 µm were acquired. The number of cells containing one or more red spots versus total cells (blue nucleus) and, in cells containing spots, the ratio r (number of red spots/cell), were determined by means of the Duolink Image tool software.
Real time (RT)-PCR assay
Total RNA was extracted from primary cultures of microglial cells treated for 48 h with vehicle (cell culture medium) or LPS plus IFN-γ (in medium). Pelleted microglial cells were treated with 1.5 mL of TRIzol Reagent (Thermo Fisher) and 300 µL of chloroform (SigmaAldrich). The aqueous phase containing total RNA was recovered after centrifugation for 15 min at 12,000×g at 4°C, mixed with 750 µL of isopropanol (Panreac) and left overnight at −80°C. Total RNA was then purified by centrifugation at 12,000×g at 4°C (15 min), washing the pellet with 70% ethanol (Panreac) and suspending the final pellet in Milli-Q water. Total RNA was quantified spectrophotometrically using a Nano Drop ND-1000 (Thermo Scientific). Total RNA (1 µg) was reversely transcribed by random priming using the High Capacity cDNA Reverse Transcription Kit from Applied Biosystems (Foster City, CA, USA). The resulting single stranded cDNA was used to perform PCR amplification for CB 2 R, and for GAPDH as an internal control using Power SYBR Green PCR Master Mix from Promega (Madison, WI, USA). Fluorescence readouts were collected using a 7500 Fast Dx Real-Time PCR Instrument from Applied Biosystems (Foster City, CA, USA). CB 2 R forward primer was: 5′-CATCACTGCCTGGCTCACT-3′ and reverse primer was: 5′-AGCATAGTCCTCGGTCCTCA-3′. In the case of GPR18, the forward primer was: 5′-TGAAGCCCAAGGTCAAGGAGAAGT-3′ and the reverse primer was: 5′-TTCATGAGGAAGGTGGTGAAGGCT-3′. In the case of GAPDH the forward/reverse primers were, respectively, 5′-CATCCTGCACCACCAACTGCTTAG-3′ and 5′-GCCTGCTTCACCACC TTCTTGATG-3′. In the absence of reverse transcription, no fluorescence was detected, thus indicating that there was no genomic DNA contamination. MIQUE guidelines were followed. Fig. 1 . Molecular interaction between CB 2 and GPR18 receptors in living cells. Confocal microscopy images of HEK-293T cells expressing CB 1 R-YFP, CB 2 R-YFP or GPR18-Rluc alone, or co-expressing CB 1 R-YFP and GPR18-Rluc or CB 2 R-YFP and GPR18-Rluc. GPR18 receptors (red) were identified by immunocytochemistry using anti-Rluc antibodies and CB 1 R and CB 2 R receptors (green) were identified by the fluorescence of YFP-containing fusion proteins (A). Co-localization is shown in the panels in the right (yellow). Cell nuclei were stained with Hoechst (blue channel). Scale bar: 10 µm. Correct functionality of the fusion proteins used in BRET assays assessed by intracellular cAMP determination assays (B). HEK-293T cells were transfected with cDNA encoding for CB 1 R, CB 1 R-YFP, CB 2 R, CB 2 R-YFP, GPR18 or GPR18-Rluc (1 µg cDNA) and cAMP production was determined after stimulation with 0.5 µM forskolin in the absence (100%) or presence of 200 nM ACEA (for CB 1 R and CB 1 R-YFP), 200 nM JWH133 (for CB 2 R and CB 2 R-YFP) or 30 nM PSB-KK-1415 (for GPR18 and GPR18-Rluc). Percentage of effect respect to the increase in cAMP levels achieved by 0.5 μM forskolin is represented. Results are the mean ± S.D. from 5 independent experiments performed in triplicates. No significant differences were found by Student's t test between effect in cells expressing the non-fused receptor or expressing the corresponding fusion protein. BRET saturation experiments performed using HEK-293T cells co-transfected with (C): GPR18-Rluc cDNA (1.6 µg) and increasing amounts of CB 1 R-YFP cDNA (0-2 µg cDNA), (D): GPR18-Rluc cDNA (1.6 µg) and increasing amounts of CB 2 R-YFP cDNA (0-2 µg cDNA), or (E): CB 1 R-Rluc cDNA (1 µg) and increasing amounts of CB 2 R-YFP cDNA (0-2.5 µg cDNA) as positive control (squares) and GABA B -Rluc cDNA (0.5 µg) and, as a negative control (circles), increasing amounts of GPR18-YFP cDNA (0-3 µg cDNA). The relative amount of BRET acceptor is given as the ratio between the fluorescence of the acceptor minus the fluorescence detected in cells only expressing the donor and the luciferase activity of the donor (YFP/Rluc). BRET data are expressed as the mean ± S.D. of six different experiments performed in duplicates. mBU: milliBret units.
Data analysis
The data in graphs are the mean ± S.D. GraphPad Prism software version 5 (San Diego, CA, USA) was used for data fitting and statistical analysis. One-or two-way ANOVA followed by post-hoc Bonferroni test were used depending of the number of factors. Two factors were considered in the case of ligand treatments (8 levels) in resting or activated cells (two levels) or in the case of ligand treatments in microglia from control or transgenic mice (two levels). PLA data in Fig. 5 were analyzed using two-way ANOVA with two levels for each factor (negative/ positive and control/transgenic). When pair of values were compared, the Student's t test was used. Significant differences were considered when p < 0.05.
Reagents
LPS and interferon-γ (IFN-γ) were purchased from SigmaAldrich (St Louis, MO, USA) and ACEA, JWH133 and SR144528 from Tocris Bioscience (Bristol, UK). PSB-KK-1415 and PSB-CB-5 were synthesized in the Department of Technology and Biotechnology of Drugs, Jagiellonian University Cracow, Poland, and provided by Prof. Christa Müller, PharmaCenter Bonn, Bonn [47, 50] .
Results
GPR18 interacts with cannabinoid CB 2 but not with CB 1 receptors
To determine whether GPR18, which belongs to the GPCR superfamily, could form heteromeric complexes with cannabinoid CB 1 or CB 2 receptors, an immunocytochemistry assay was first developed to assess the potential colocalization of GPR18 and cannabinoid receptors in cotransfected cells. To do so, the heterologous HEK-293T cell-expression system was used. Cells were transfected with cDNAs for CB 1 R-YFP (green, top left panel in Fig. 1A) , CB 2 R-YFP (green, top center panel in Fig. 1A ) or GPR18-Rluc (red, top right panel in Fig. 1A ). Receptor expression was detected by YFP's own fluorescence for CB 1 R or CB 2 R, or using an anti-Rluc antibody and a secondary Cy3-conjugated antibody for GPR18. As observed in Fig. 1A , all three receptors were found in different cell compartments including the plasma membrane. Moreover, when HEK-293T cells were transfected with cDNAs for GPR18-Rluc and either for CB 1 R-YFP or CB 2 R-YFP, both GPR18/CB 1 R and GPR18/CB 2 R showed a significant degree of co-localization (Fig. 1A) . Indeed, co-localization does not prove a direct interaction; hence, to demonstrate physical interactions between receptor pairs, a BRET 1 type energy transfer approach was used. We checked that all cannabinoid and GPR18 receptor-fusion proteins properly trafficked to the cell membrane, as shown by confocal microscopy, and were functional, as shown by similar ability to decrease forskolin-induced cAMP levels as that of native proteins (Fig. 1B) . BRET was undertaken in HEK-293T cells expressing a constant amount of cDNA for GPR18-Rluc and increasing amounts of cDNA for CB 1 R-YFP. An unspecific linear signal was obtained, indicating the lack of interaction between CB 1 and GPR18 receptors (Fig. 1C) . A similar linear relationship was obtained for the negative control consisting of HEK-293T cells expressing a constant amount of GABA B R-Rluc and increasing amounts of GPR18-YFP (Fig. 1E) . However, when a similar experiment was developed transfecting HEK-293T cells with a constant amount of cDNA for GPR18-Rluc and increasing amounts of cDNA for CB 2 R-YFP, a saturation BRET curve (BRET max 227 mBU, BRET 50 47.5) was obtained, thus indicating a specific interaction between GPR18 and CB 2 receptors (Fig. 1D) increasing amounts of CB 2 R-YFP (Fig. 1E) . These results indicate that GPR18 may form heteroreceptor complexes with CB 2 but not with CB 1 receptors.
Functional characterization of CB 2 -GPR18 heteroreceptor complexes in HEK-293T cells
It is well established that CB 2 R couples to heterotrimeric G i proteins and its activation inhibits adenylate cyclase thus decreasing intracellular cAMP levels [27] . Some authors have reported that GPR18 may also couple to G i [24] . Accordingly, we first determined cAMP levels in forskolin-treated HEK-293T cells expressing CB 2 R, GPR18 or both. Agonist concentrations were selected from preliminary dose-response experiments in which the ability of JWH133 or PSB-KK-1415 to decrease forskolin-induced cAMP levels was assayed using HEK-293T cells expressing, respectively, CB 2 R or GPR18 ( Fig. 2A,B) . On the one hand, the selective CB 2 R agonist, JWH133 (100 nM), decreased forskolin-induced cAMP levels in HEK-293T cells expressing the receptor, and induced a small non-statistically significant effect in cells expressing GPR18 (Fig. 3A,B) . On the other hand, PSB-KK-1415 (30 nM), a selective GPR18 agonist, induced a significant decrease in cAMP levels in forskolin-treated HEK-293T cells expressing the receptor, while having no effect in CB 2 R-expressing cells (Fig. 3A,B) . Moreover, the CB 2 R selective antagonist, SR144528 (1 µM) inhibited the JWH133 induced effect in CB 2 R-expressing cells (Fig. 3A) , while PSB-CB-5 (1 µM), a selective GPR18 receptor antagonist, counteracted the PSB-KK-1415-induced effect in GPR18-expressing cells (Fig. 3B) . In HEK-293T cells expressing both CB 2 and GPR18 receptors, JWH133 decreased cAMP levels to a similar extent to that observed in cells only expressing CB 2 R. In contrast, the treatment with PSB-KK-1415 was ineffective, thus suggesting that the simple expression of CB 2 R blocks the PSB-KK-1415-induced GPR18 activation and signaling. Finally, when cotransfected cells were simultaneously treated with the two agonists, no effect was observed (Fig. 3C ). Such negative cross-talk may be used as a print to detect the GPR18-CB 2 heteroreceptor complexes in natural sources. Although the pretreatment with GPR18 receptor antagonist PSB-CB-5 (1 µM) slightly decreased the JWH133 induced effect in cotransfected cells, no significant differences were found compared to the single JWH133 treatment (Fig. 3C) .
MAPK engagement, which may be mediated by G-protein- dependent and independent mechanisms, was also analyzed. Agonist concentrations were selected from dose-response experiments of JWH133 or PSB-KK-1415 treatments in which ERK1/2 phosphorylation in HEK-293T cells expressing CB 2 R or GPR18, respectively, was tested (Fig. 2C,D) . In CB 2 R-expressing HEK-293T cells JWH133 specifically increased ERK1/2 phosphorylation, while PSB-KK-1415 induced no effect (Fig. 3D) . In GPR18-expressing cells, PSB-KK-1415 (30 nM) induced a significant effect while the CB 2 R selective agonist had no effect (Fig. 3E) . In HEK-293T cells expressing the two receptors both JWH133 and PSB-KK-1415 induced a small effect when used individually but the effect was reduced when used in combination (Fig. 3F) . Accordingly, a negative cross-talk was also observed in MAPK signaling. Interestingly, in cotransfected cells pretreated with the selective CB 2 R antagonist SR144528 (1 µM) or with the selective GPR18 receptor antagonist PSB-CB-5 (1 µM), the effect of both JWH133 and PSB-KK-1415 on ERK1/2 phosphorylation was counteracted; thus a cross-antagonism effect was detected on both directions (Fig. 3F) . Uni-or bi-directional cross-antagonism constitute reliable heteromer prints. DMR, which is a labelfree method to measure cellular mass movements induced upon receptor activation, was determined in cells expressing either receptor. JWH133 or PSB-KK-1415 provided significant real-time DMR recordings by, respectively, activating CB 2 R or GPR18 receptors (Fig. 3G,H) . Interestingly, the cross-talk and cross-antagonism detected in cAMP determination and MAPK signaling assays were also observed in cells expressing both receptors (Fig. 3I) . These results show receptor heteromerization and a functional cross-talk that is due to reflects reflects the molecular interaction and that is disclosed by negative cross-talk and/or cross-antagonism.
Functional characterization of CB 2 -GPR18 heteroreceptor complexes in primary cultures of microglia
Our next aim was to address the physiological relevance of the finding of heteromers in a heterologous expression system. Accordingly, we performed assays to identify heteroreceptor complexes in primary cultures of microglia. Proximity ligation assays (PLA) were performed using specific antibodies against cannabinoid CB 2 and GPR18 receptors (see Methods) and punctuated red marks were visualized surrounding DAPI-stained nuclei, demonstrating the existence of CB 2 -GPR18 receptor complexes/clusters. The absence of the primary anti-GPR18 antibody (negative control) led to a marked reduction of the PLA signal (Fig. 4A,B, untreated) . To get insights into the functional role of CB 2 R-GPR18 heteroreceptor complexes in microglial cells, cAMP intracellular levels and MAPK pathway activation were determined. In both assay types, treatment of microglia with JWH133 or PSB-KK-1415 induced a significant effect that was decreased when the cells were simultaneously treated with both ligands. Then, a negative cross-talk was also detected in primary cultures of microglia (Fig. 4D,E, untreated) . Moreover, pretreatment of the primary cultures with the selective GPR18 antagonist PSB-CB-5 (1 µM) counteracted not only the PSB-KK-1415-induced ERK1/2 phosphorylation, but also the JWH133-induced effect. Cross-antagonism was also detected when SR144528 was used as it blocked both JWH133 and PSB-KK-1415 actions (Fig. 4E) . Thus, cross-antagonism was also detected in resting microglia.
GPR18-CB 2 R negative cross-modulation in activated microglia
It has been described that CB 2 R expression increases in activated microglia and that the receptor then plays a relevant role in regulating the production of neuroinflammatory mediators [42, 38] . Our next aim was to assess the structural and functional implication of CB 2 -GPR18 heteroreceptor complexes in primary microglia activated by 48-h treatment with 1 µM LPS plus 200 U/mL IFN-γ (see Ref. [38] ). The relative expression of transcripts for both CB 2 R and GPR18 was analyzed by RT-PCR in microglia from wild type mice treated or not with LPS plus IFN-γ. mRNA specific for either CB 2 R or GPR18 significantly increased in activated cells (Fig. 4C) . By comparing microglial primary cultures treated or not with 1 μM LPS plus 200 U/mL IFN-γ, PLA results showed CB 2 -GPR18 receptor heteromer expression in both resting and activated cells (Fig. 4A,B) . We then determined the effect of agonists on cAMP levels and ERK1/2 phosphorylation. Interestingly, microglia treated with 1 μM LPS plus 200 U/mL IFN-γ showed an increase in CB 2 R-and GPR18-induced signaling. The statistical analysis showed an interaction between cell activation (LPS plus IFN-γ) and receptor activation by agonists. While all the functional results showed a negative cross-talk, cross-antagonism (bidirectional) was identified in pERK but not in cAMP assays (Fig. 4D,E) .
3.5. CB 2 R-GPR18 heteromer expression and function assayed in primary microglia from APP Sw,Ind transgenic mice Two-day-old pups obtained from APP Sw,Ind × WT mice crossings were individually genotyped and classified as non-transgenic (control) or heterozygous APP transgenic mice (APP Sw,Ind ). In adulthood the APP Sw,Ind mouse displays brain amyloid plaques and neuroinflammatory responses, including reactive microglia and cognitive deficits [37] . Primary cultures of microglia were prepared from both control and APP Sw,Ind mice. It should be noted that microglia from APP Sw,Ind do show an activated phenotype (see Ref. [38] ).
To detect differential expression in CB 2 -GPR18 receptor complexes in control and transgenic animals, PLA assays were developed using primary cultures of microglia obtained from control and APP Sw,Ind mice. Significant differences were found between wild-type and APP Sw,Ind mice both in the percentage of cells displaying red clusters (61% in control vs 73% in APP Sw,Ind mice) and in the number of dots/cell in cells displaying dots (3.5 in control vs 5.0 in APP Sw,Ind mice) (Fig. 5A,B) .
Cultures were also used to determine signaling upon agonist activation. We first analyzed the cAMP levels in forskolin-treated primary cultures of microglia from non-transgenic and APP Sw,Ind mice. Activation with the CB 2 R selective agonist (JWH133, 300 nM) or with the GPR18 selective agonist (PSB-KK-1415, 100 nM) slightly decreased cAMP levels in microglia from controls, while it had a significantly higher effect on microglia from APP Sw,Ind mice (Fig. 5C) . Interestingly, statistical analysis showed an interaction between mice genotype and agonist treatment. Simultaneous activation of the two receptors led to a negative cross-talk both in control and APP Sw,Ind animals (Fig. 5C ). The effect of JWH133 on ERK1/2 phosphorylation was significantly higher in microglia from APP Sw,Ind and the analysis using two-way ANOVA showed an interaction between mice genotype and ligand treatment. When cells from APP Sw,Ind mice were pretreated with a CB 2 R selective antagonist (SR144528, 1 µM) or with a GPR18 selective antagonist (PSB-CB-5, 1 µM), the effect of the two agonists was abolished, indicating a bidirectional cross-antagonism (Fig. 5D) .
To sum up, activated microglia or microglia from APP Sw,Ind mice showed the heteromer print, an increase in the expression of CB 2 R, of GPR18, and of CB 2 R-GPR18 heteromers and a potentiation in specific signaling.
Discussion
Despite GPR18 and GPR55 may respond to cannabinoid molecules, the physiological role of the receptors and their signal transduction mechanisms are unclear. Neither they are considered real cannabinoid receptors nor share sequence similarity. Furthermore, pharmacological characterization is very incomplete due to shortage in pharmacological tools. In such a scenario, there is the possibility, proven for GPR55 [2, 29, 36] , but not for GPR18 that these receptors may form heteromers with cannabinoid receptors. The consequences of heteroreceptor complex formation are multiple as it may result in cross-inhibition in some signaling pathways investigated in some expression system, but in potentiation in the case of activated microglia. In fact, CB 2 R in resting microglia are not well coupled to G i , whereas in activated cells, overexpressed CB 2 R are robustly coupled to G i and such finding correlates with a significant increase in the expression of CB 1 R/CB 2 R heteromers [38] .
GPR55 may also form heteromers with either CB 1 or CB 2 receptors. Two different laboratories demonstrated that CB 2 R may form heteromers with GPR55. In one of them the study of receptor heteromerization was linked to cancer because GPR55 is overexpressed in many cancerous cells [36] . The second paper showed heteromer formation and its signaling consequences in a heterologous expression system [2] . The presence of the partner receptor in the heteromer affected signal transduction from both CB 2 R and GPR55. Co-expression of CB 2 R and GPR55 led to a reduction in GPR55-mediated activation of transcription factors and DMR signal, while MAPK pathway activation was potentiated. When CB 2 R activation was assayed, co-expression of CB 2 R and GPR55 negatively modulated CB 2 R-mediated MAPK pathway activation and DMR signals [2] . GPR55 may also form heteromers with CB 1 R as reported from work not only in heterologous expression systems but in rodent and non-human primate models. A significant amount of CB 1 -GPR55 heteroreceptor complexes are expressed in the corpus striatum of the rat, as demonstrated by detecting the heteromer print consisting of cross-antagonism, i.e. blockade of signaling of one receptor by the antagonist of the partner receptor in the heteromeric complex. In situ PLA assays served to confirm expression of CB 1 R-GPR55 complexes in the caudate and putamen nuclei of a non-human primate [29] .
The endocannabinoid system suffers profound changes in neurodegenerative diseases, especially in those with an inflammatory component [5] . CB 1 R and CB 2 R are both expressed in microglia, where CB 2 R regulates CB 1 R signaling, and under inflammatory conditions CB 2 R expression and signaling are upregulated, and the negative crosstalk between CB 1 R and CB 2 R turns into synergy when both receptors are co-activated [38] . Walter et al. [54] demonstrated that pathological stimulation of microglia triggered microglial cell migration by engaging CB 2 R and receptors for abnormal cannabidiol, i.e. GPR18. GPR18 mRNA and protein expression was found in microglial cells, where NAGly, seemingly through GPR18, regulates migration and produces phenotypic switches, being a potent pro-migratory lipid [33] [34] 32] .
We here show using BRET 1 that GPR18 may interact with cannabinoid receptors but unlike GPR55, which may interact with both, GPR18 establishes receptor complexes with CB 2 but not with CB 1 receptors. This differential trend is relevant and shows that GPCR-GPCR interactions are not promiscuous, i.e. further to the need of being expressed in the same cell, the two interacting receptors should have complementary interfaces to be able to establish direct molecular contacts and display novel functional properties [40, 39] . The functionality of the CB 2 R-GPR18 heteromer was studied in HEK-293T cells at the level of different signaling pathways. In all of them (intracellular cAMP accumulation, ERK1/2 phosphorylation and DMR), a negative cross-talk was detected, i.e. when both receptors are activated, the signal does not become additive but is reduced. The negative crosstalk, which may be considered a heteromer print, indicates that GPR18 activation places a brake to the action of cannabinoids acting on CB 2 R. Another heteromer print, namely bidirectional cross-antagonism, was also identified. As CB 2 R is considered a receptor that may mediate neuroprotection [14, 48, 21] , microglia-expressed CB 2 R-GPR18 receptor complexes may be targets for neuroprotection. In fact, the complex was expressed both in resting microglia and in primary cultures of microglia treated with 1 μM LPS plus 200 U/mL IFN-γ. Upon microglial activation, CB 2 R and GPR18 expression and signaling were upregulated, while the negative cross-talk was maintained. In AD and in the APP Sw,Ind mice AD model, inflammatory parameters are present in cortex and hippocampus [37, 12, 7] . Indeed the APP Sw,Ind model of AD has been described to display reactive astrocytes and activated microglia [37, 49] . In the Fig. 5 . CB 2 -GPR18 receptor heteromer expression and function in primary cultures of microglia from the APP Sw,Ind mice. Proximity Ligation Assay (PLA) was performed as described in Methods in primary cultures of microglia cells from two-day-old wild-type (control) and APP Sw,Ind mice using specific primary antibodies against CB 2 R and GPR18. Representative images corresponding to stacks of 5 sequential planes are shown (A). Cell nuclei were stained with Hoechst (blue) and heteroreceptor complexes appear as red dots. Scale bar: 20 μm. (B) Ratio (r; number of red spots/cell-containing spots) and percentage of cells containing one or more red spots (numbers above each bar graphs) are the mean ± S.D. of counts in 4 different fields from every sample (n = 5). Two-way ANOVA for factors amount of red dots and control (white bars)/APP Sw,Ind (black bars) showed statistical differences ( # p < 0.05). Panels C, D: Primary cultures of microglial cells of two-day-old wildtype (control, white bars) and APP Sw,Ind (black bars) mice were pre-treated with selective receptor antagonists (1 μM SR144528 for CB 2 R or 1 μM PSB-CB-5 for GPR18) and subsequently treated with selective agonists (300 nM JWH133 for CB 2 R or 100 nM PSB-KK-1415 for GPR18), alone or in combination. cAMP accumulation (C) was detected by TR-FRET in the presence of 0.5 μM forskolin. cAMP production is expressed as % of levels obtained by 0.5 µM forskolin. ERK1/2 phosphorylation (D) was analyzed using an AlphaScreen®SureFire® kit (Perkin Elmer) ERK1/2 phosphorylation data are expressed as % respect to basal levels. Values are the mean ± S.D. of 6 different experiments performed in triplicates. Two-way ANOVA for factors ligand and control/APP Sw,Ind showed statistical differences ( microglial cultures from of APP Sw,Ind mice brain, we found similar results to those obtained in microglia from wild-type animals treated with LPS/IFN-γ. Apart from the heteromer print, the activated microglia "phenotype", i.e. an increase of receptors-mediated signaling, was identified and the amount of CB 2 R-GPR18 heteroreceptor complexes increased when compared to data generated using samples from control animals. All these data suggest that CB 2 R-GPR18 complexes deserve attention as potential targets for the treatment of neuroinflammation occurring in neurodegenerative diseases.
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